An Open-Label Phase 1b Clinical Study of Intravenous CAVATAK® (Coxsackievirus A21, CVA21), in Combination With Ipilimumab in Subjects With Uveal Melanoma Metastatic to Liver (VLA-024 CLEVER)

Trial Profile

An Open-Label Phase 1b Clinical Study of Intravenous CAVATAK® (Coxsackievirus A21, CVA21), in Combination With Ipilimumab in Subjects With Uveal Melanoma Metastatic to Liver (VLA-024 CLEVER)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Mar 2018

At a glance

  • Drugs CVA 21 (Primary) ; Ipilimumab
  • Indications Uveal melanoma
  • Focus Adverse reactions
  • Acronyms CLEVER
  • Sponsors Viralytics
  • Most Recent Events

    • 23 Jan 2018 Status changed from planning to recruiting.
    • 23 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top